BOSULIF vs HYFTOR

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated June 7, 2026·How we rate

Possible drug interaction. BOSULIF and HYFTOR are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	BOSULIF	HYFTOR
Rating	New	New
Pharmacy pays	—	~$48.61 /30
Type	RX	RX
Active ingredient	BOSUTINIB MONOHYDRATE	SIROLIMUS
Manufacturer	Pf Prism Cv	Nobelpharma
Dosage forms	Capsule, Tablet	Topical
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Bcr-Abl Positive Chronic Myelogenous Leukemia	Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

bosulif hyftor

Rating

New

Pharmacy pays

—

~$48.61 /30

Type

Active ingredient

BOSUTINIB MONOHYDRATE

SIROLIMUS

Manufacturer

Pf Prism Cv

Nobelpharma

Dosage forms

Capsule, Tablet

Topical

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Bcr-Abl Positive Chronic Myelogenous Leukemia

Lymphangioleiomyomatosis, Perivascular Epithelioid Cell Neoplasms

Frequently asked questions

What is the difference between Bosulif and Hyftor?

Bosulif contains Bosutinib Monohydrate, while Hyftor contains Sirolimus — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.